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Summary:  Hydroxyapatite (HAP) is the main inorganic component of human 
skeleton. The last years a lot of interest is focused on its use as drug carrier. In this 
work the in vitro adsorption of the anti-cancer drug oxaliplatin, by HAP, from its 
aqueous solution was studied. Various initial concentrations of oxaliplatin aqueous 
solutions were used in order to determine the maximum adsorption capacity of HAP. 
Oxaliplatin’s concentrations were determined through Pt determinations by atomic 
absorption spectrometry with flame technique, in the equilibrated solutions after 
shaking for 48 hours and filtering the HAP-oxaliplatin slurries. The maximum 
adsorption capacity was found to be 49.1 mg oxaliplatin/g HAP. In order to determine 
the time needed for the maximum adsorption to be achieved, six oxaliplatin – HAP 
slurries were prepared. The slurries had initial oxaliplatin concentrations the one that 
corresponds to the maximum adsorption capacity of the HAP added. The oxaliplatin 
determination was carried out after 0, 10, 20, 30, 40 and 48 hours in each different 
slurry. The maximum adsorption capacity was achieved after 20 hours. The adsorption 
of oxaliplatin by HAP was found to follow the Freundlich equation.  
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1. INTRODUCTION 
 
The development of new drug delivery systems using novel 
materials such as ceramics and polymers for the treatment of several 
diseases presents high scientific interest. Major purpose is to achieve 
a controlled and slow release rate of the drug in order to insure a 
constant in vivo drug concentration for a longer period of time and to 
prevent harmful side-effects [1-7]. 
 
Many forms of ceramic drug delivery systems have been used to 
carry various types of drugs such as proteins, steroids, hormones, 
amino acids, phenolics, vaccines, antibiotics and anti-cancer drugs. BIO
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One of the most commonly used ceramic form is HAP 
[Ca10(OH)2(PO4)6] which is biocompatible, since it is the essentially 
hard, inorganic component of human bones. Furthermore physical 
and chemical properties of HAP as chemical composition, structure, 
porosity, particle size, surface area and ionic composition of the 
equilibrating solution are determinant in drugs’ binding and release 
[1, 4, 8-12].  
 
Several studies related to the application of HAP as drug carrier, 
have been published. Yammamura et. al. [13] investigated the load 
of the antibiotic Cefotiam in samples of porous HAP for the purpose 
of prevention and avoidance infections during surgical process 
placing HAP implant. Otsuka et. al. [14] developed a drug-delivery 
system for use in patients with chronic arthritis, chronic articular 
rheumatics and other diseases, after surgery. It consists of a self - 
setting bioactive calcium phosphate cement containing aspirin. 
Barroug and Glimcher [1], studied the characteristics of the in vitro 
binding and release of the anticancer drug cisplatin by slurries of 
synthetic HAP crystals carried out in aqueous media and found that 
they depend significantly on the ionic composition of the aqueous 
media used [1, 13-14].  
 
The purpose of the present work was to study the adsorption of an 
anticancer drug oxaliplatin by HAP. The next step in our work will 
be the study of the release of oxaliplatin by HAP. Final target is to 
develop a HAP impregnated with oxaliplatin implant which will act 
also as a drug delivery system. Oxaliplatin is an antineoplastic agent 
belonging to a new class of platinum based compounds in which the 
platinum atom is complexed with 1,2-diaminocyclohexane (DACH) 
and an oxalate group (Fig. 1). 
 
 
Fig. 1. Molecular structure of oxaliplatin 
(cis-[(1R,2R)-1,2-cyclohexane diamine-N,N']) [17] 
 
Oxaliplatin acts as an alkylating cytotoxic agent, inhibiting DNA 
replication by forming adducts between two adjacent guanine plus BIO
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adenine. It is the main drug for the treatment of colorectal cancer and 
it, also, prevents antitumor activity in the treatments of pancreatic, 
gastric, ovarian, bladder, breast, small and non-small cell lung, head 
and neck cancer [15-18]. 
 
2. MATERIALS AND METHODS 
 
2.1. Materials 
 
HAP was purchased from Riedel – de Haen in the form of tri - 
calcium phosphate extra pure [Ca5(PO4)3OH]. Oxaliplatin was used 
as its commercial form, Eloxatin (5 mg/ml). The bottle contains 100 
mg oxaliplatin and 900 mg lactose monohydrate as vehicle and was 
supplied by Theageneion Cancer Hospital of Thessaloniki. Platinum 
atomic absorption standard solution (1 mg/ml Pt in 10% HCl) was 
bought from Acros Organics. All the materials were stored at room 
temperature. 
 
2.2. Methods 
 
2.2.1. Adsorption of oxaliplatin by HAP 
For the determination of the maximum amount of oxaliplatin that can 
be adsorbed by HAP, eloxatin was dissolved in double deionized 
water (10 ml) by rapid mixing in glass flasks in order to produce 
solutions of various concentrations ranging from 92 to 30000 mg/l. 
Twelve samples were prepared by dispersion of HAP (50 mg) in 
each one of these solutions. The samples were shaked in a shaker for 
48 hours and filtered. In the filtrate Pt was determined. 
 
For the study of the kinetic of the adsorption, samples were prepared 
by the same way as above using initial concentration of oxaliplatin 
that corresponds to maximum adsorbed amount, determined. 
Afterwards the samples were shaked and every ten hours one of 
them was filtered. Pt was determined in the filtrate. 
 
2.2.2. Determination of platinum concentration 
Initial and final concentrations of Pt in solutions were determined by 
atomic absorption spectrometry with flame technique, using a Perkin 
Elmer 503 spectrophotometer. Pt standards for calibration were 
prepared by dilution of stock solution. The calibration curve covered 
the range of 0 to 50 ppm. All the presented values were the mean of 
three replicates. BIO
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3. RESULTS AND DISCUSSION 
 
3.1. Results 
 
The amounts of adsorbed oxaliplatin by HAP as a function of the 
residual concentration at equilibrium are presented in Table 1. The 
adsorbed oxaliplatin increases as its initial concentration increases 
until a maximum amount of 49.1 mg/g is reached. This amount 
corresponds to the 26.2% of the initially available oxaliplatin. This 
could be attributed to the fact that oxaliplatin co-exist with the 
vehicle, lactose monohydrate. As result, a part of HAP’s surface is 
covered by the vehicle preventing the adsorption of oxaliplatin. 
 
Table 1. Adsorption of oxaliplatin by HAP 
Concentration 
Cin (mg/l)           Ceq (mg/l) 
Amount Adsorbed 
Q (mg/g) 
4.11 4.04  0.015 
6.45 6.36  0.016 
7.78 7.63  0.032 
12.89 12.70  0.038 
14.21 13.99  0.044 
24.86 24.63  0.047 
64.46 55.72  1.749 
174.97 150.47  4.900 
526.85 378.16  29.739 
576.30 420.30  31.200 
939.89 694.39  49.100 
1013.16 769.16  48.800 
Cin: Initial concentration 
Ceq: Final concentration after 48 hours equilibration 
Equilibrium pH = 6.5 
 
The adsorption of oxaliplatin by HAP is well described 
mathematically by the Freundlich isotherm (Fig. 2), defined by the 
relationship: Q = KFCeq
1/n, where Q is the amount of solute adsorbed 
per unit weight of adsorbent, Ceq  is the residual liquid phase 
concentration at equilibrium, KF and 1/n are characteristics 
constants. The equation linearizes in logarithmic form: BIO
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lnQ = lnKF +1/n Ceq
 
for parameter evaluation. It was found that 
KF  = 0.00067 and 1/n = 1.737 [19]. 
 
The adsorption kinetic of oxaliplatin by HAP is presented in Fig. 3. 
The maximum adsorption value was achieved in 20 hours and 
remains the same for the next 28 hours. 
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Fig. 2. Freundlich adsorption isotherm of oxaliplatin by HAP: 
natural logarithm of the amount of oxaliplatin adsorbed per gram 
HAP (lnQ) vs. natural logarithm of the oxaliplatin equilibrium 
concentration (lnCeq). (Equilibration time: 48 hours) 
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Fig. 3. Kinetic of adsorption of oxaliplatin by HAP 
(Q: amount of oxaliplatin adsorbed per 1 gram HAP) 
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3.2. Discussion 
 
This study shows that a reasonable amount (49.1 mg/g) of oxaliplatin 
can be adsorbed by HAP. This amount could be altered with the addition 
of different amounts of vehicle (lactose monohydrate).The advised dose 
of oxaliplatin is 85 mg/m
2 of body-surface area (BSA) intravenously 
every two weeks [15]. The "normal" BSA is generally taken to be 1.7 m
2 
but, in actual fact, the BSA depends on more than just height and 
weight. Other influential factors include the age and gender of the 
individual. So average BSA for adult men is 1.9 m
2 and for adult women 
1.6 m
2 [20]. According to these, a man patient has to take 161.5 mg 
oxaliplatin every 2 weeks, which can be delivered by 3.3 g HAP. The 
equivalent dose for a woman patient is 136 mg oxaliplatin every 2 
weeks, which can be delivered by 2.8 g HAP.  
 
Since oxaliplatin is given intravenously only a small amount of a dose is 
expected to reach to the tumor. The rest creating serious side effects on 
human organism [21]. The amount of 49.1 mg oxaliplatin per 1g HAP 
indicates that a porous HAP implant or a paste could be loaded with 
enough quantity of oxaliplatin possibly to complete required treatments.  
 
The matter that arises and will be investigated in our future work is the 
kinetics of release of oxaliplatin from HAP in SBF (simulated body 
fluid). It is expected the release to be completed in some days. 
 
Moschidis A. et. al [22], studied in vivo the anticancer action of 
oxaliplatin against murine pancreatic adenocarcinoma PAN02. 
According to these experiments, the constituting dose for a mouse is 
6.78 mg/kg [22, 23]. On the basis that the mean weight of a mouse is 25 
g, the administered dose is 0.17 mg oxaliplatin / mouse. Considering that 
the requisite dose of oxaliplatin is similar in the case of bone cancer, this 
quantity can be carried by 0.02 g HAP.  
 
4. CONCLUSION 
 
HAP was found to adsorb 49.1 mg oxaliplatin per gram, which 
corresponds to the 26.2% of the initially available oxaliplatin of the 
oxaliplatin / lactose monohydrate (10/90) system. The maximum 
oxaliplatin’s adsorption by HAP was achieved in 20 hours. The amount 
adsorbed and the kinetic of adsorption suggest the possible use of the 
system as drug carrier in the case of implants or paste but further release 
and in vivo experiments are needed. BIO
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